M05.40, Rheumatoid myopathy with rheumatoid arthritis of unspecified site

CGS-J15-L39427, MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis

J15

CGS-J15-L34394, Visual Fields Testing

J15

CGS-J18-L39427, MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis

J18

CGS-J18-L34394, Visual Fields Testing

J18

WPS-J5-L39481, MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis

J5

A59434, Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

J5

A59536, Billing and Coding: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis

J5

A58893, Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

J6

NGS-J6-L33394, Drugs and Biologicals, Coverage of, for Label and Off-Label Uses

J6

NGS-J6-L39297, Off-label Use of Rituximab and Rituximab Biosimilars

J6

A52423, Billing and Coding: Infliximab and biosimilars

J6

A59101, Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars

J6

WPS-J8-L39481, MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis

J8

A57657, Billing and Coding: Sedimentation Rate, Erythrocyte

J9

FIRST_COAST-L34021, Sedimentation Rate, Erythrocyte

J9

A59764, Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

J9

NOVITAS-JH-L36007, Lower Extremity Major Joint Replacement (Hip and Knee)

JH

NOVITAS-JH-L39063, Pharmacogenomics Testing

JH

NOVITAS-JH-L35062, Biomarkers Overview

JH

NGS-JK-L39297, Off-label Use of Rituximab and Rituximab Biosimilars

JK